Missing Data Hinders Inclusion Of Patient Experience In Drug Labeling, US FDA Says

 
• By Brenda Sandburg
  
Patient data
Missing data on trial endpoints can limit drug label claims • Source: Shutterstock

More from US FDA

More from Agency Leadership